Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Teneligliptin Hydrobromide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 901Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 13Canalia

    02 17Tenelia

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    euroPLX 90 Lisbon
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    euroPLX 90 Lisbon
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 222

    2019 Revenue in Millions : 230

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 137

    2019 Revenue in Millions : 112

    Growth (%) : 22

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 80

    2019 Revenue in Millions : 69

    Growth (%) : 16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2020 Revenue in Millions : 138

    2019 Revenue in Millions : 147

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 139

    2020 Revenue in Millions : 136

    Growth (%) : 11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 200

    2020 Revenue in Millions : 220

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 84

    2020 Revenue in Millions : 79

    Growth (%) : 15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2021 Revenue in Millions : 133

    2020 Revenue in Millions : 137

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Canalia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Canalia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Mitsubishi Tanabe

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 73

    2021 Revenue in Millions : 88

    Growth (%) : -16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Tenelia

    Teneligliptin, Canagliflozin

    arrow
    BIO CEO & Investor
    Not Confirmed

    Brand Name : Tenelia

    Japan
    arrow
    BIO CEO & Investor
    Not Confirmed

    Daiichi Sankyo

    Teneligliptin, Canagliflozin

    Main Therapeutic Indication : Diabetes

    Currency : USD

    2022 Revenue in Millions : 170

    2021 Revenue in Millions : 200

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.